Ambroxol hydrochloride 15.0 mg: An orange-yellow, circular lozenge with a characteristic orange odour.
Pharmacology: Pharmacodynamics: Preclinically, ambroxol has been shown to increase respiratory tract secretion. It enhances pulmonary surfactant production and stimulates ciliary activity. These actions result in improved mucus flow and transport (mucociliary clearance has been shown in clinical pharmacologic studies. Enhancement of fluid secretion and mucociliary clearance facilitates expectoration and eases cough.
Pharmacokinetics: Ambroxol hydrochloride is a metabolite of bromhexine which is a mucolytic agent used in the treatment of respiratory disorders associated with viscid or excessive mucus. It alters the structure of mucus to decrease its viscosity and therefore, facilitate its removal by ciliary action or expectoration.
Strepsils Chesty Cough is a mucolytic lozenge specially formulated to help in clearing the airway by thinning of excessive tenacious mucus in chesty cough.
Recommended Dosage: Adults: Up to 6 lozenges to be sucked per day, with maximum of 2 lozenges per dose.
Children 6-12 years: Not recommended unless under the advice of a healthcare professional.
Children under 6 years: Not indicated in children under 6 years.
Route of Administration: Oral.
Overdose and Treatment: No symptoms of overdosage have been reported in man to date. If they occur, symptomatic treatment should be provided.
Allergy of hypersensitivity to ambroxol or any of the ingredients listed.
If symptoms persist, consult a doctor.
Very rare cases of chronically associated severe skin impairments such as Stevens-Johnson Syndrome, Toxic Epidermal Necrolysis (TEN), Erythema Multiforme (EM) and Acute Generalized Exanthematous Pustulosis (AGEP) have been reported. In most cases, these could be explained by the severity of the underlying disease or concomitant administration of another drug. In the early stages of such severe skin reactions, initially only nonspecific flu-like symptoms appear, e.g. fever, arthralgia, runny nose, cough, and sore throat. If skin or mucous membrane damage occurs, seek medical advice immediately and discontinue treatment as a precaution.
The usual precautions regarding the use of drugs during pregnancy, especially during the first trimester, should be observed.
During breastfeeding, Strepsils Chesty Cough Lozenge should be used only if absolutely necessary.
Strepsils Chesty Cough is generally well tolerated. However, mild upper gastrointestinal adverse reactions such as mouth dryness, nausea, vomiting and diarrhoea have been reported. Allergic reactions have occurred rarely, primarily skin rashes and hypersensitivity.
Immune System Disorders: Frequency not known: Anaphylactic reactions including anaphylactic shock.
Skin and Subcutaneous Skin Disorders: Frequency not known: Severe skin reactions (including Stevens-Johnson syndrome, Toxic epidermal necrolysis (TEN), Erythema Multiforme (EM) and Acute Generalized Exanthematous Pustulosis (AGEP).
Administration of ambroxol together with antibiotics (amoxicillin, cefuroxime, erythromycin, doxycycline) leads to higher antibiotic concentration in the lung tissue. No clinically relevant unfavourable interaction with other medications have been reported.
R02AD05 - ambroxol ; Belongs to the class of local anesthetics used in throat preparations.
Strepsils Chesty Cough loz 15 mg
24 × 8's;24's;8's
Sign Out
Continue with Google
Sign up with email
Already a member?
Sign in
